The global incidence of sexually transmitted infections (STIs) remains high, with the World
Health Organization (WHO) estimating that over 1 million people acquire STIs daily. STIs …

Urogenital tract infections with Chlamydia trachomatis have frequently been detected among
patients diagnosed with sexually transmitted infections, and such infections lead to …

A licensed Chlamydia trachomatis (Ct) vaccine is not yet available. Recombinant Chlamydia
trachomatis major outer membrane protein (Ct-MOMP), the most abundant constituent of the …

Chlamydia trachomatis is the leading cause of bacterial sexually transmitted infection (STI)
and remains a major public health challenge, especially in less-developed regions …

The significant impact of Chlamydia trachomatis (Ct) infections worldwide highlights the
need to develop a prophylactic vaccine that elicits effective immunity and protects the host …

Chlamydia trachomatis is a strict intracellular human pathogen. It is the main bacterial cause
of sexually transmitted infections and the etiologic agent of trachoma, which is the leading …

The Pgp3 subunit vaccine elicits immune protection against Chlamydia trachomatis
infection, but additional adjuvants are still required to enhance its immunoprotective efficacy …

Chlamydia trachomatis is an obligate intracellular pathogen responsible for the most
prevalent bacterial sexually transmitted disease globally. The high prevalence of chlamydial …

Chlamydia trachomatis, a Gram-negative bacterium that infects the rectum, urethra,
congenital sites, and columnar epithelium of the cervix. It is a major cause of preventable …

Targeted therapy is an attractive approach for treating infectious diseases. Affibody
molecules have similar capability to antibodies that facilitate molecular recognition in both …